Fibroneer-ON: An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) (FIBRONEER™-ON)

The main objective is to assess the long-term tolerability, safety, and efficacy of oral BI 1015550 treatment in patients with IPF and other types of PPF who have completed planned treatment (and did not prematurely discontinue trial medication permanently in the pivotal Phase III parent trials, 1305-0014 [FIBRONEER™-IPF] or 1305-0023 [FIBRONEER™-ILD]).